Opinion: To secure the U.S.'s biotech supply chain, pay attention to domestic companies

Scientific breakthroughs will enable a future of personalized drug discovery, where precision medicine makes it possible to receive the right dose of the right medicine at the right time. America’s ability to lead this global frontier of medicine is contingent upon our willingness to recognize China as a competitor and respond accordingly. But often overlooked in this essential conversation is the importance of investing more in U.S. biotech firms and innovation ecosystems — including those outside of the well-recognized hubs.

Two critical ingredients need to be protected — and developed — to deliver on the promise of accessible precision medicine: the genomic data and intellectual property that propel drug discovery and development.

Read the rest…